MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Supernus Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

32.83 4.06

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

31.13

Max

32.89

Belangrijke statistieken

By Trading Economics

Inkomsten

-23M

15M

Verkoop

-1.5M

174M

K/W

Sectorgemiddelde

24.811

63.778

EPS

0.548

Winstmarge

8.801

Werknemers

674

EBITDA

-20M

45M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+22.47% upside

Dividenden

By Dow Jones

Volgende Winsten

7 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-272M

1.8B

Vorige openingsprijs

28.77

Vorige sluitingsprijs

32.83

Nieuwssentiment

By Acuity

16%

84%

28 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Supernus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 apr 2024, 18:04 UTC

Belangrijke Marktbewegers

Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready

Peer Vergelijking

Prijswijziging

Supernus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

22.47% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 38.8 USD  22.47%

Hoogste 44 USD

Laagste 36 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Supernus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

2

Buy

3

Hold

0

Sell

Technische score

By Trading Central

31.63 / 32.28Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

28 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.